Business
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
– Expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 – – Expects 2024 adjusted EBITDA of greater than $150 million –
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Expects high-single digit percentage LINZESS® EUTRx prescription demand growth in 2024 –\n\n\n– Expects 2024 adjusted EBITDA of greater than $150 million –\n\n\n BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced financial guidance for full year 2024. The results were announced in advance of the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference, which will take place on Wednesday, January 10, 2024 at 11:15 a.m. PT / 2:15 p.m. ET.\n\n\n“We believe the significant progress we made across our strategic priorities last year has strengthened our position to be the leading GI healthcare company,” said Tom McCourt, chief executive officer of Ironwood. “We are on track to deliver on our 2023 LINZESS U.S. net sales guidance, driven by continued strong prescription demand and remain encouraged about the future growth potential of the brand. Furthermore in 2023, we strengthened our GI pipeline with the addition of apraglutide, which we believe has blockbuster potential in short bowel syndrome requiring parenteral support, if approved.”\n\n\n“Looking ahead in 2024, we remain committed to maximizing LINZESS, advancing our GI development pipeline and delivering profits and cash flows. We expect to deliver another year of high-single digit percentage LINZESS demand growth and maintain class-leading formulary access, which we believe will result in low-single digit percentage LINZESS U.S. net sales growth in 2024. In addition, we expect to deliver greater than $150 million in adjusted EBITDA in 2024. We are looking forward to an exciting and potentially transformational year for Ironwood with several catalysts ahead of us, highlighted by the topline data from our STARS Phase 3 study expected in March in SBS-IF and topline data from the ongoing Phase 2 study for CNP-104 expected in the third quarter. We believe the advancement of our pipeline programs, combined with continued strong LINZESS demand growth, uniquely position our company for success in our mission to be the leader in GI.”\n\n\nFull Year 2023 Financial Guidance and Full Year 2024 Financial Guidance\n\n\nIronwood is maintaining its previous FY 2023 financial guidance and is providing FY 2024 financial guidance.\n\n\n\n\n \n\n\n\n\n\n\nFY 2023 Guidance\n\n\n\n\n(November 2023)\n\n\n\n...